Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 7/20 | 0.67 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.65 |
| ▸ | TNIK | Q9UKE5 | 11/20 | 0.64 |
| ▸ | AXL | P30530 | 2/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.60 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113498 | 0.91 | AXL (0.62) | MAP3K11MAP4K1TNIKAXL | |
| SCHEMBL4126100 | 0.89 | MAP4K1 (0.65) | MAP3K11MAP4K1TNIKAXL | |
| SCHEMBL4112313 | 0.86 | AXL (0.59) | MAP3K11MAP4K1TNIKAXL | |
| SCHEMBL27667239 | 0.83 | MAP3K11 (0.65) | MAP3K11MAP4K1TNIKIKBKBCHUK | |
| SCHEMBL22971621 | 0.81 | MAP3K11 (0.74) | MAP3K11MAP4K1TNIKIKBKBCHUK | |
| SCHEMBL4119636 | 0.81 | MAP4K1 (0.67) | MAP4K1AXLCDK2 | |
| SCHEMBL7513626 | 0.81 | TNIK (0.75) | MAP3K11MAP4K1TNIKIKBKBCHUK | |
| SCHEMBL22971589 | 0.80 | MAP3K11 (0.84) | MAP3K11MAP4K1TNIKIKBKBCHUK | |
| SCHEMBL12066038 | 0.80 | MAP3K11 (1.00) | MAP3K11MAP4K1TNIKIKBKBCHUK | |
| SCHEMBL28502500 | 0.80 | MAP3K11 (0.73) | MAP3K11MAP4K1TNIKIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018130-A1 | Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | claimed |
| US-20090018130-A1 | Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018130-A1 | Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid | AADAC, PAH, PDE7A | MAP3K11 1133/4885MAP4K1 939/4885TNIK 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.